Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry W B Johnson

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 7, 2005
Total synthesis of gambierol: subunit coupling and completionHenry W B Johnson, Utpal Majumder, Jon D Rainier
Journal of the American Chemical Society|January 20, 2005
The total synthesis of gambierolHenry W B Johnson, Utpal Majumder, Jon D Rainier
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 7, 2005
Total synthesis of gambierol: the generation of the A-C and F-H subunits by using a C-glycoside centered strategyUtpal Majumder, Jason M Cox, Henry W B Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2009
A polyether biotoxin binding site on the lipid-exposed face of the pore domain of Kv channels revealed by the marine toxin gambierolIvan Kopljar, Alain J Labro, Eva Cuypers, et al.
Cardiovascular Research|December 4, 2022
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosisJun Li, Shaobo Hu, Henry W B Johnson, et al.
Journal of Medicinal Chemistry|November 2, 2018
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide)Henry W B Johnson, Eric Lowe, Janet L Anderl, et al.
Frontiers in Immunology|March 27, 2023
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responsesTony Muchamuel, R Andrea Fan, Janet L Anderl, et al.
ACS Medicinal Chemistry Letters|April 25, 2017
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) SubunitHenry W B Johnson, Janet L Anderl, Erin K Bradley, et al.
Journal of Medicinal Chemistry|January 5, 2012
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonistsMohamed A Ibrahim, Henry W B Johnson, Joon Won Jeong, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 7, 2005
Total synthesis of gambierol: subunit coupling and completionHenry W B Johnson, Utpal Majumder, Jon D Rainier
Journal of the American Chemical Society|January 20, 2005
The total synthesis of gambierolHenry W B Johnson, Utpal Majumder, Jon D Rainier
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 7, 2005
Total synthesis of gambierol: the generation of the A-C and F-H subunits by using a C-glycoside centered strategyUtpal Majumder, Jason M Cox, Henry W B Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2009
A polyether biotoxin binding site on the lipid-exposed face of the pore domain of Kv channels revealed by the marine toxin gambierolIvan Kopljar, Alain J Labro, Eva Cuypers, et al.
Cardiovascular Research|December 4, 2022
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosisJun Li, Shaobo Hu, Henry W B Johnson, et al.
Journal of Medicinal Chemistry|November 2, 2018
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide)Henry W B Johnson, Eric Lowe, Janet L Anderl, et al.
Frontiers in Immunology|March 27, 2023
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responsesTony Muchamuel, R Andrea Fan, Janet L Anderl, et al.
ACS Medicinal Chemistry Letters|April 25, 2017
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) SubunitHenry W B Johnson, Janet L Anderl, Erin K Bradley, et al.
Journal of Medicinal Chemistry|January 5, 2012
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonistsMohamed A Ibrahim, Henry W B Johnson, Joon Won Jeong, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)Craig S Takeuchi, Byung Gyu Kim, Charles M Blazey, et al.
Pageof 2